25 results about "Fasting glucose" patented technology

The invention provides a sugar fat disease death risk prediction method and system based on NHANES data, and the method comprises the steps: obtaining the fasting blood glucose FPG and glycosylated hemoglobin HbA1c clinical detection data of a sugar fat disease patient, and calculating an SHR value through a formula; based on the data of the NHANES database, SHR total cause bilateral critical values of total cause death rate and cardiovascular death rate, SHR cardiovascular bilateral critical values and SHR cancer unilateral critical values of cancer death rate are obtained; and comparing the SHR value with an SHR total cause double-side critical value, an SHR cardiovascular double-side critical value and an SHR cancer single-side critical value of the cancer death rate, and carrying out risk layering and evaluation. The biochemical aging acceleration index has a prediction effect on the diabetes death risk, and KDMAgeAccel significantly intermediates the death risk caused by SHR.

The present invention relates to a computer-implemented method for aiding in the guidance of diabetes drug therapy of an individual suffering from diabetes mellitus. The method is based on glucose data from said individual that are received at a processing unit, wherein said glucose data comprise at least three fasting glucose measurement values from said individual, and / or at least three matched pre-prandial glucose measurement values and postprandial glucose measurement values at the same meal from said individual. Further contemplated by the present invention is a device for aiding in the guidance of drug diabetes therapy of an individual suffering from diabetes, said device comprising a processing unit, and a computer program including computer-executable instructions, wherein said instructions, when executed by the processing unit, causes the processing unit to perform the computer-implemented method of the present invention.

This specification discloses FABP inhibitor compounds and their use in pharmaceutical compositions for treating diseases that highly express any of these FABPs, including cancers, particularly triple-negative breast cancer (TNBC), and other pro-inflammatory diseases, including cardiovascular diseases, obesity or obesity-related disorders, diabetes, dyslipidemia, impaired glucose tolerance or impaired fasting blood glucose, vitiligo, psoriasis, autoimmune disorders, pain, and dementia. This specification also discloses methods for preparing the disclosed compounds.

The compositions and methods for improving or regulating GLP-1 levels, stimulating GLP-1 secretion, ameliorating metabolism including losing weight, managing glucose or insulin tolerance including stimulating insulin secretion, inhibiting glucagon secretion and reducing fasting glucose levels. The compositions comprise β-aminoisobutyric acid, a physiologically acceptable salt, polymer, ester, or 3-hydroxy-3-methylbutanoic acid, a physiologically acceptable salt, polymer, ester, or tributyrin or tributyrin derivative, or mixture thereof.

The invention provides application of nitraria tangutorum bobr extract in preparation of products for regulating glycolipid metabolism disorder, and relates to the technical field of plant extract application. The nitraria macrocarpa extract is a composition rich in alkaloid and flavonoid compounds, wherein the sum of the content of total alkaloid and the content of total flavonoids is not lower than 85% of the total weight of the extract. The extract is prepared through the processes of fresh fruit juicing, alcohol precipitation impurity removal and AB-8 macroporous resin gradient elution. Experiments show that the extract can significantly reduce fasting blood glucose of type 2 diabetes mice induced by high-fat and high-sugar diet combined with STZ, improve sugar tolerance and insulin resistance, and synchronously regulate the blood fat level, and shows an excellent glucose and lipid metabolism synergistic improvement effect. The extract disclosed by the invention provides a choice for developing a safe and effective glycolipid metabolism regulator.

The invention relates to the technical field of medical artificial intelligence, and particularly discloses a method for establishing a disease prediction model of GCK-MODY in gestational diabetes population based on machine learning. The model takes five clinical characteristics as input variables: a body mass index before pregnancy, fasting blood glucose and glycosylated hemoglobin levels during GDM diagnosis, continuous multi-generation diabetes family history and a newly discovered predictive factor, namely GDM diagnosis week of pregnancy. A classification model is constructed through a support vector machine algorithm, and a SHapley additive interpretation method is adopted to provide global and local interpretation of a prediction result, so that model transparency is enhanced. The area of the model under a curve in a test is obviously superior to that of an existing screening standard. The invention also provides an electronic device, a storage medium and a prediction system comprising the model, which can assist clinicians in early recognition of GCK-MODY high-risk patients, provide decision support for targeted gene detection, avoid unnecessary enhanced hypoglycemic treatment of pregnant women, reduce the risk of maternal and infant complications, and promote precise medical development of gestational diabetes mellitus.

This invention relates to the field of clinical evaluation technology, specifically a stratified randomized controlled trial method for evaluating the intervention of traditional Chinese medicine compound formulas in prediabetes. The method includes the following steps: constructing stratified codes for subjects based on fasting blood glucose differences; constructing a blood glucose change difference sequence by combining the differences before and after intervention; using a regression function to obtain characteristic inflection points and establish a dose interval mapping relationship; obtaining the peak blood glucose time based on glucose tolerance tests and segmenting the time axis; calculating the slope characteristic parameters of each segment; and classifying and judging the comprehensive parameters and mapping relationship to construct a efficacy grading evaluation index. In this invention, by comparing multiple fasting blood glucose differences with stable parameters to extract fluctuation characteristics, a stratified coding mechanism is constructed to avoid the risk of stratification mismatch in a single test. The intervention difference is extracted and used to introduce piecewise linear regression to calculate the slope and capture the response characteristic inflection points. Combined with standard comparison, the degree of recovery of the body is determined, and the curve shape is transformed into a multi-dimensional efficacy grading index, effectively improving clinical precision.

The invention discloses application of indoleacetic acid in diagnosis and treatment of gestational diabetes mellitus. Clinical queue research finds that the concentration of serum indoleacetic acid of pregnant women in a gestational diabetes mellitus group is remarkably lower than that of pregnant women in a healthy control group, and high diagnosis efficiency is achieved. Animal experiments further prove that in a high fat diet induced mouse model with gestational diabetes mellitus, the exogenous indoleacetic acid is supplemented, so that the fasting blood glucose of a female mouse with gestational diabetes mellitus can be reduced, abnormal glucose tolerance and insulin resistance can be improved, and the indoleacetic acid is free of embryotoxicity, safe and reliable. The application provides a new thought and means for early diagnosis and effective treatment of gestational diabetes mellitus, and has a wide application prospect.

Described herein are methods of treatment of metabolic syndrome using Cannabis Plant Material to reduce fasting glucose and insulin and lower the homeostasis model assessment-estimated insulin resistance (HOMA-IR) index to mitigate metabolic syndrome and associated Type II Diabetes, Coronary Heart Disease, and Stroke, pharmacological compounds for same and methods for making the pharmacological compounds.

The invention relates to the technical field of medicine, in particular to application of PC (17: 0 / 0: 0) in preparation of medicine for improving glucose metabolism disorder, clinical research finds that the level of serum PC (17: 0 / 0: 0) is in significant negative correlation with fasting blood-glucose and is in significant positive correlation with the levels of serum odd-chain fatty acids (C15: 0, C17: 0 and C19: 0). Mechanism research shows that PC (17: 0 / 0: 0) can be directly combined with and activate PPARalpha so as to up-regulate HACL1 expression and promote synthesis of endogenous odd-chain fatty acid, so that insulin sensitivity and glucose homeostasis are improved, and a new strategy is provided for developing PC (17: 0 / 0: 0)-based hypoglycemic drugs or health-care foods for assisting in regulating blood sugar.

The invention discloses a prediction model for enteral nutrition intolerance occurrence risk of an adult patient with severe burn and application thereof, and belongs to the field of disease risk prediction. According to the method, risk factors of enteral nutritional feeding intolerance of the serious burn patient are screened, and the EFI risk prediction model of the adult serious burn patient is established and verified based on a Logistic regression analysis method, so that a scientific basis is provided for early clinical recognition of high-risk patients and implementation of preventive intervention. Risk factors for occurrence of EFI (Extensible Firmware Index) of severe burn patients of adults are explored, the risk factors comprise the number of basic diseases of subjects, whether intestinal probiotics are used or not, the number of white blood cells within 24 hours of hospital admission, fasting blood-glucose within 24 hours of hospital admission and the total area of burn, and a risk prediction model is constructed based on the risk factors. And reference is provided for early clinical recognition of high-risk groups with intolerant enteral nutrition feeding of serious burn patients.

The present application relates to the technical field of biotechnology, and discloses a plant Lactobacillus plantarum XKFY202518 and application of the plant Lactobacillus plantarum XKFY202518 in preparation of a type 2 diabetes auxiliary preparation for improving insulin resistance and regulating blood lipid, the plant Lactobacillus plantarum XKFY202518 has a preservation number of CGMCC No.34745 in China General Microbiological Culture Collection Center, and a preservation date of June 3, 2025.The plant Lactobacillus plantarum XKFY202518 separated by the present application can effectively reduce the fasting blood glucose level, insulin level, total cholesterol level, triglyceride level, low-density lipoprotein cholesterol level, alanine aminotransferase level and aspartate aminotransferase level of a diabetic mouse, and increase the high-density lipoprotein cholesterol level of the mouse serum, thereby improving the hyperglycemia and hyperlipidemia symptoms of a type 2 diabetes mouse.

The invention relates to lactobacillus paracasei KXW5 with a hypoglycemic function and application thereof, and belongs to the technical field of microorganisms. In order to excavate a microecological preparation for treating hyperglycemia-related diseases, a strain of lactobacillus paracasei KXW5 is separated, and in-vivo and in-vitro experiments prove that the strain has remarkable blood sugar reducing capacity, including promoting proliferation of high-glucose-induced INS-1 cells, improving the relative expression quantity of MafA genes in the high-glucose-induced INS-1 cells and improving the blood sugar reducing capacity. The fasting blood glucose level, postprandial blood glucose level, insulin resistance level, glycosylated hemoglobin level, liver copper ion level and the expression level of copper death related genes FDX1 and DLAT in the liver of the type II diabetes mellitus patient are reduced, and the oral glucose tolerance of the type II diabetes mellitus patient is enhanced. The strain KXW5 provided by the invention can be used for preparing medicines for reducing blood sugar and preventing and / or treating diabetes mellitus or health-care foods for assisting in reducing blood sugar, and opens up a new way for preventing and treating diabetes mellitus.

Disclosed herein are FABP inhibitor compounds and their use in pharmaceutical compositions for the treatment of diseases, including cancers that highly express any of FABP, particularly triple negative breast cancer (TNBC), and other inflammation-inducing diseases, including cancer that highly express any of FABP. Comprise cardiovascular diseases, obesity or obesity-related diseases, diabetes, dyslipidemia, impaired blood glucose tolerance or impaired fasting blood glucose, vitiligo, psoriasis, autoimmune diseases, pain and dementia. Also disclosed herein are methods for preparing the disclosed compounds.

The invention relates to non-systemic TGR5 agonist useful in the treatment of chemotherapy-induced diarrhea, diabetes, Type II diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during short bowel syndrome, and irritable bowel syndrome (IBS), and other TGR5 associated diseases and disorders, having the Formula:where R1, R2, R2′, R3, R4, X1, X2, X3, X4, Q, and n are described herein.

Methods, devices and system for determining fasting glucose level information and post-prandial glucose level information for diagnosing pre-diabetic and diabetic conditions based on monitored glucose measurements are provided.

The invention discloses a continuous blood glucose monitoring graphical interface with a fasting blood glucose reference line and a display method. The reference line for prompting whether blood glucose reaches the standard or not in a fasting state is drawn in a coordinate axis in a glucose tendency chart of the graphical interface. The reference line is a horizontal line with visual identification characteristics and is used for assisting a user in identifying the blood glucose state in the fasting time period in a graphical interface, the reference value can be dynamically set according to user attributes and is a blood glucose threshold value used for judging the fasting state medically, and the value range is flexibly configured according to medical guidelines and individual conditions; a set time period is supported to control the display; when the real-time blood glucose value exceeds the reference value, reminding mechanisms such as pattern highlighting and message pushing can be triggered. According to the method, the graphic auxiliary value of the continuous glucose monitoring system in fasting blood glucose control is enhanced, and the method is different from a display mode that only a general high / low blood glucose warning line is arranged in an existing system, and has individuation and clinical adaptation capacity.

The invention discloses a method and equipment for optimizing the initial four-time injection dosage of a weekly insulin preparation, and the method comprises the steps: obtaining corresponding information used for calculating the first injection dosage W1 before the first injection of the weekly insulin preparation; determining W1 according to the acquired corresponding information; determining a second injection regulation coefficient k2 and a second injection dosage W2 according to the fasting blood glucose gear and W1 after the first injection of the periinsulin preparation and before the second injection of the periinsulin preparation; determining a third injection regulation coefficient k3 and a third injection dosage W3 according to fasting blood glucose gears, W1, k2 and W2 after the second injection of the periinsulin preparation and before the third injection of the periinsulin preparation; and determining a third injection regulation coefficient k4 and a third injection dosage W4 according to fasting blood glucose gears, W1, k2, W2, k3 and W3 after the third injection of the periinsulin preparation and before the fourth injection of the periinsulin preparation. According to the invention, a more scientific basis can be provided for the initial four-time injection dosage of the weekly preparation.

Disclosed herein are FABP inhibitor compounds and their use in pharmaceutical compositions for treating diseases including cancers that highly express any of these FABPs, in particular triple-negative breast cancer (TNBC), hepatocellular carcinoma and other inflammation-induced diseases including cardiovascular disease, obesity or an obesity-related disorders, diabetes, dyslipidemia, impaired glucose tolerance or impaired fasting glucose, vitiligo, psoriasis, viral infection, pain and dementia. Also disclosed herein are methods for preparing the disclosed compounds.

Disclosed herein are FABP inhibitor compounds and their use in pharmaceutical compositions for treating diseases including cancers that highly express any of these FABPs, in particular triple-negative breast cancer (TNBC), hepatocellular carcinoma and other inflammation-induced diseases including cardiovascular disease, obesity or an obesity-related disorders, diabetes, dyslipidemia, impaired glucose tolerance or impaired fasting glucose, vitiligo, psoriasis, viral infection, pain and dementia. Also disclosed herein are methods for preparing the disclosed compounds.

The invention relates to the technical field of pregnant woman delivery time prediction, in particular to a pregnant woman delivery time prediction system based on big data analysis, and the system carries out the weighted fusion of the ratio of the abdominal circumference of a fetus to the femur length, a fetus weight estimation value and a fetus weight increase rate to obtain a fetus metabolic load index; calculating to obtain an insulin resistance index change rate according to the fasting insulin level and the fasting blood glucose level; calculating the blood glucose fluctuation amplitude of the continuous blood glucose monitoring data of the maternal body, and calculating the area abnormal increment under the blood glucose curve; analyzing the blood glucose fluctuation amplitude, the insulin resistance index change rate and the abnormal increment of the area under the blood glucose curve to obtain a maternal metabolic stress index; and when a dynamic imbalance critical value obtained by carrying out load-stress imbalance analysis on the fetal metabolic load index and the maternal metabolic stress index exceeds a preset dynamic imbalance critical threshold value, generating predicted delivery time and outputting early warning information. And the accuracy of predicting the delivery time of the pregnant woman with the gestational diabetes mellitus is effectively improved.

The disclosure relates to the use of phosphodiesterase 1 (PDE1) inhibitors for treatment or prophylaxis for a metabolic disorder (e.g., obesity, fatty liver disease, type 2 diabetes, pre-diabetic conditions, and conditions associated with fat-induced inflammation), reducing high blood glucose levels (e.g. as reflected in high fasting glucose or Hb-A1C levels), and / or promoting or maintaining body weight loss or suppressing body weight gain.

The invention discloses a detection kit for early diagnosis of diabetes mellitus. The detection kit comprises a fasting blood glucose detection reagent used for evaluating the instant blood glucose condition in the body of a patient; the glycosylated hemoglobin detection reagent is used for evaluating the average blood sugar level of the patient in nearly 2-3 months; the serum C peptide detection reagent is used for evaluating the function level of insulin secretion of pancreatic beta cells of the patient; the serum cystatin C detection reagent is used for evaluating the kidney tissue injury condition of a patient. According to the detection kit, multi-level collaborative detection and comprehensive analysis are carried out by combining multiple detection methods, an accurate and sensitive diabetes diagnosis result can be obtained, the probability of missed diagnosis and misdiagnosis can be effectively reduced, and the detection kit is of great significance especially for early accurate diagnosis of diabetes. In addition, the detection kit also has the advantages of high accuracy, high safety, high sensitivity, low price, wide range of people suitable for detection and the like, and is very suitable for current clinical requirements.

The invention discloses a method and equipment for calculating the injection dose of a periinsulin preparation. The method comprises the following steps: acquiring a single injection pharmacokinetic model of the periinsulin preparation, historical injection information of a patient using the periinsulin preparation, a fasting blood glucose value monitored during the period of using the periinsulin preparation by the patient and a dose estimated value of the injection; according to the acquired single injection pharmacokinetic model, the historical injection information, the fasting blood glucose value and the dose estimation value, predicting fasting blood glucose of the patient in a next week after the patient injects the periinsulin preparation according to the dose estimation value; according to whether the fasting blood glucose of the next week is within the fasting blood glucose target range of the patient or not, whether the dose estimation value needs to be adjusted or not is judged, and the dose estimation value is adjusted based on the judgment result so that the adjusted injection dose estimation value can meet the requirement. The injection dosage can enable a patient to reach a steady state as soon as possible, and the injection dosage can be compatible with occasionally irregular injection modes.

The invention discloses application of ketoisophorone and benzyl benzoate in preparation of a medicine for treating diabetes, and belongs to the technical field of biological medicine. In-vivo and in-vitro studies find that after a T2DM animal model and a GlcN cell model are treated through KSP independent administration, BZT independent administration and KSP and BZT 1: 3 combined administration, compared with a model group, the blood glucose regulation effect of a combined administration group is most remarkable: the area under an fasting blood glucose and oral glucose tolerance test (OGTT) curve is in dose-dependent reduction, and the area under the curve is in dose-dependent reduction; an insulin tolerance test (ITT) result shows that the insulin sensitivity is obviously improved; in animal experiments, glycogen generation in liver tissues is increased, and balloon-like deformation and fatty degeneration accumulation conditions are relieved.